Last 48 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.30 | — | — | — | — | — | — | — | 0.18 | 1.11 | 0.24 | — | — | — | — | — | — | 2.45 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6467.26 | — | — | — | 1424.54 | — | — | — | 101.31 | 102.86 | — | — | 3.19 | 5.99 | 1.93 | 10.80 | 13.25 | 0.52 | 13.65 | 17.43 | 221.49 |
| — | — | — | — | +1306.1% | — | — | — | +3071.6% | +1616.0% | — | — | -75.9% | +1046.8% | -85.9% | -38.0% | -94.0% | -98.7% | -48.4% | -88.5% | +518.1% | |
| P/B Ratio | 1.12 | 1.93 | 1.80 | 4.39 | 4.05 | 1.94 | 0.52 | 0.69 | 0.58 | 4.86 | — | — | 1.00 | 0.39 | — | — | — | — | — | 12.89 | 8.41 |
| — | -0.5% | +247.5% | +539.7% | +592.1% | -60.0% | — | — | -41.4% | +1162.4% | — | — | — | — | — | — | — | — | — | +49.2% | -3.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.37 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.05 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 0.23 | 0.01 | — | — | — | — | — | — | 2.07 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | — | — | 100.0% | — | — | — | 54.7% | 386.7% | — | — | 138.7% | -1.7% | -10.1% | -949.1% | 30.8% | 96.5% | -51.7% | 38.6% | -3900.0% |
| — | — | — | — | +82.9% | — | — | — | -60.6% | +22918.3% | — | — | +350.3% | -101.8% | +80.4% | -2557.5% | +100.8% | +194.6% | +73.7% | -53.9% | -540.6% | |
| Operating Margin | -123601.7% | — | — | — | -33461.0% | — | — | — | -6932.8% | -5165.1% | — | — | -656.9% | -1589.0% | -1112.0% | -1850.9% | -988.3% | 27.4% | -1145.0% | -1777.7% | -8202.3% |
| — | — | — | — | -382.6% | — | — | — | -955.4% | -225.1% | — | — | +33.5% | -5900.7% | +2.9% | -4.1% | +88.0% | +102.2% | -44.5% | +72.5% | -68.6% | |
| Net Margin | -132642.4% | — | — | — | -23254.2% | — | — | — | -18405.7% | 9251.8% | — | — | -1430.5% | -2215.3% | -1274.2% | -2095.8% | -1095.1% | 21.4% | -1257.2% | -1879.9% | -8765.3% |
| — | — | — | — | -26.3% | — | — | — | -1186.7% | +517.6% | — | — | -30.6% | -10474.6% | -1.3% | -11.5% | +87.5% | +101.7% | -146.6% | +71.0% | -738.8% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -72.4% | -4.3% | -14.1% | -25.9% | -15.7% | -31.2% | -18.3% | -10.3% | -45.9% | 617.0% | — | — | -74.3% | -135.3% | — | — | — | — | -6626.0% | -149.9% | -60.6% |
| — | +86.3% | +23.1% | -152.1% | +65.7% | -105.1% | — | — | +38.2% | +555.9% | — | — | — | — | — | — | — | — | -10503.0% | -41.0% | -22.2% | |
| ROA | -58.6% | -3.9% | -12.3% | -18.1% | -11.4% | -24.3% | -15.7% | -9.1% | -28.4% | 22.3% | 84.9% | -167.6% | -32.5% | -19.5% | -27.1% | -28.6% | -28.1% | 9.3% | -27.6% | -31.0% | -21.9% |
| — | +84.0% | +21.4% | -99.6% | +59.9% | -209.2% | -118.5% | +94.6% | +12.7% | +214.0% | +413.2% | -486.0% | -15.8% | -310.5% | +1.8% | +7.8% | -28.4% | +142.5% | -2.8% | +45.8% | +28.0% | |
| ROIC | -159.3% | -4.8% | -11.6% | -27.2% | -22.0% | -22.5% | -47.2% | — | — | — | — | — | -102.7% | -87.5% | -390.3% | — | — | 231.1% | -490.7% | -921.6% | -811.6% |
| — | +78.8% | +75.5% | — | — | — | — | — | — | — | — | — | — | -137.9% | +20.5% | — | — | +100.8% | — | +74.1% | -1.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.00 | 0.00 | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | 0.00 | 0.03 | — | — | 0.07 | 0.04 | — | — | — | — | — | 5.31 | 1.44 |
| — | -94.2% | -91.7% | +421.6% | +584.4% | -76.8% | — | — | -94.2% | -28.5% | — | — | — | — | — | — | — | — | — | +49247.4% | +8222.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.74 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 8.14 | 16.63 | 19.31 | 7.66 | 8.14 | 14.28 | 12.44 | 22.61 | 19.96 | 1.42 | 0.99 | 0.52 | 1.82 | 2.11 | 0.33 | 0.83 | 0.74 | 1.07 | 0.98 | 2.44 | 3.11 |
| — | +16.5% | +55.2% | -66.1% | -59.2% | +905.8% | +1150.6% | +4284.8% | +997.7% | -32.6% | +197.1% | -37.8% | +144.9% | +96.7% | -65.7% | -66.1% | -76.1% | -73.5% | -55.4% | +39.5% | +82.1% | |
| Quick Ratio | 8.14 | 16.63 | 19.31 | 7.66 | 8.14 | 14.28 | 12.44 | 22.61 | 19.96 | 1.42 | 0.99 | 0.52 | 1.82 | 2.11 | 0.33 | 0.83 | 0.74 | 1.07 | 0.97 | 2.44 | 3.11 |
| — | +16.5% | +55.2% | -66.1% | -59.2% | +905.8% | +1150.6% | +4284.8% | +997.7% | -32.6% | +197.8% | -37.7% | +145.2% | +96.9% | -65.7% | -66.1% | -76.1% | -73.5% | -55.4% | +39.5% | +82.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | -2.41 | -7.18 | -9.26 | -9.33 | 4.56 | -10.25 | -17.86 | -15.17 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AVTX stock.
Avalo Therapeutics, Inc.'s current P/E is -4.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Avalo Therapeutics, Inc.'s current operating margin is -123601.7%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Avalo Therapeutics, Inc.'s business trajectory between earnings reports.